Published April 10, 2013 | Version v1
Journal article

Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?

  • 1. Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, 9038 (Norway)
  • 2. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, 8092 (Norway)

Description

Recent studies from Italy, Japan and Norway have confirmed previous reports, which found that a large variety of palliative radiotherapy regimens are used for painful bone metastases. Routine use of single fraction treatment might or might not be the preferred institutional approach. It is not entirely clear why inter-physician and inter-institution differences continue to persist despite numerous randomized trials, meta-analyses and guidelines, which recommend against more costly and inconvenient multi-fraction regimens delivering total doses of 30 Gy or more in a large number of clinical scenarios. In the present mini-review we discuss the questions of whether doctors are ignoring evidence-based medicine or whether we need additional studies targeting specifically those patient populations where recent surveys identified inconsistent treatment recommendations, e.g. because of challenging disease extent. We identify open questions and provide research suggestions, which might contribute to making radiation oncology practitioners more confident in selecting the right treatment for the right patient

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-85; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643865

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 85
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47062126
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
GY RANGE 10-100; METASTASES; RADIOTHERAPY; RECOMMENDATIONS; SKELETON
Descriptors DEC
ABSORBED DOSE RANGE; BODY; GY RANGE; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2013 Nieder et al.
Notes
PMCID: PMC3643865; PUBLISHER-ID: 1748-717X-8-85; PMID: 23574944; OAI: oai:pubmedcentral.nih.gov:3643865; licensee BioMed Central Ltd.